Clinical and Life Sciences · 28 September 2026 to 28 September 2026 · 1 headlines · STAT
STAT Plus: Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’
GLP-1 drugs, initially framed as obesity treatments for patients, are increasingly being marketed and used as lifestyle medications for customers.
As it ran
28 September 2026
More from US healthcare
- Rising health insurance costs for healthcare workers 27 September 2026
- STAT Plus: Cadre of radiopharmaceuticals experts pushes the bounds in cancer therapy 28 September 2026
- I discovered a new structure in the heart — just by looking closely 28 September 2026
- Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth Disorder 27 September 2026
- FDA's gene therapy approval and accelerated drug review programs 26 September 2026
- FDA issues draft guidance on premarket submissions of robotically-assisted surgical devices 26 September 2026
- 2 Hot Dogs or 1 Large Cookie? A Study of Risks by Amount of Ultraprocessed Food 25 September 2026
- 3 Common Drugs Older Adults Might Be Overusing 25 September 2026